Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Opebacan

Drug Profile

Opebacan

Alternative Names: BPI 21; Neuprex; rBPI21; Recombinant bactericidal permeability increasing protein 21

Latest Information Update: 03 Aug 2010

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator New York University
  • Developer XOMA
  • Class Antibacterials; Recombinant proteins
  • Mechanism of Action Angiogenesis inhibitors; Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Meningococcal infections

Highest Development Phases

  • No development reported Meningococcal infections; Postoperative infections; Radiation injuries; Wound infections
  • Discontinued Graft-versus-host disease; Post-traumatic infections

Most Recent Events

  • 03 Aug 2010 Discontinued - Phase-I/II for Graft-versus-host disease in USA (Parenteral)
  • 09 Jan 2007 Phase-I/II clinical trials in Graft-versus-host disease in USA (Parenteral)
  • 06 Sep 2006 Opebacan has received orphan drug status for Meningococcal infections in the European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top